{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:19:06Z","timestamp":1792509546699,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Thrombocytopenia is the most common hematologic manifestation of acid sphingomyelinase deficiency (ASMD). The introduction of enzyme replacement therapy (ERT) represents significant progress in the treatment landscape of this disorder. This study presents the largest pediatric case series of ASMD to date, providing valuable insights into the real-world application of ERT in affected children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Ten children with ASMD (five with type B and five with type A\/B) received ERT for one year. Growth parameters, complete blood counts, abdominal ultrasonography, liver function tests, lipid profiles, and neurological assessments were conducted at baseline and subsequently every three months. In addition, chest high-resolution computed tomography (HRCT) and dual-energy X-ray absorptiometry (DXA) were performed at baseline and repeated after one year.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No serious infusion-related reactions (IAR) were recorded. However, one patient developed a mild urticarial rash, while another experienced pyrexia. Anemia was present in all children at baseline. A significant increase in hemoglobin levels starting at week 12 (<jats:italic>p<\/jats:italic>\u2009=\u20090.02) with peak levels observed at week 50. Thrombocytopenia was present in 60% of patients at baseline. Platelet counts did not show a significant change at week 12 (<jats:italic>p<\/jats:italic>\u2009=\u20090.3), but a significant increase was observed after 24 weeks (<jats:italic>p<\/jats:italic>\u2009=\u20090.0196), and counts peaked at week 50 (<jats:italic>p<\/jats:italic>\u2009=\u20090.0057). There was a significant reduction in liver and spleen sizes, as well as lipid profile parameters. In addition, gradual improvements were observed in interstitial lung disease scores and bone mineral densities throughout the study course.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Our findings indicate that olipudase alfa provides significant benefits in key hematological and visceral clinical outcomes in pediatric patients with ASMD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40348-025-00199-9","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T04:23:50Z","timestamp":1755145430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcome of enzyme replacement therapy for hematological and visceral manifestations in children with acid sphingomyelinase deficiency: a single center experience in upper Egypt"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9054-0662","authenticated-orcid":false,"given":"Mervat A. M.","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa Hefzy","family":"Shaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahed A M","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"199_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","volume":"120","author":"EH Schuchman","year":"2017","unstructured":"Schuchman EH, Desnick RJ (2017) Types A and B Niemann-Pick disease. Mol Genet Metab 120:27\u201333","journal-title":"Mol Genet Metab"},{"key":"199_CR2","doi-asserted-by":"crossref","unstructured":"Brady RO, Kanfer JN, Mock MB, Fredrickson DS (1966) The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick diseae. Proceedings of the National Academy of Sciences.;55:366\u20139","DOI":"10.1073\/pnas.55.2.366"},{"key":"199_CR3","doi-asserted-by":"crossref","unstructured":"Pentchev PG, Comly ME, Kruth HS, Vanier MT, Wenger DA, Patel S et al (1985) A defect in cholesterol esterification in Niemann-Pick disease (type C) patients. Proceedings of the National Academy of Sciences.;82:8247\u201351","DOI":"10.1073\/pnas.82.23.8247"},{"key":"199_CR4","doi-asserted-by":"publisher","first-page":"12870","DOI":"10.3390\/ijms222312870","volume":"22","author":"C Pinto","year":"2021","unstructured":"Pinto C, Sousa D, Ghilas V, Dardis A, Scarpa M, Macedo M (2021) Acid Sphingomyelinase deficiency: A clinical and immunological perspective. Int J Mol Sci 22:12870","journal-title":"Int J Mol Sci"},{"key":"199_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13023-023-02686-6","volume":"18","author":"T Geberhiwot","year":"2023","unstructured":"Geberhiwot T, Wasserstein M, Wanninayake S, Bolton SC, Dardis A, Lehman A et al (2023) Consensus clinical management guidelines for acid Sphingomyelinase deficiency (Niemann\u2013Pick disease types A, B and A\/B). Orphanet J Rare Dis 18:85","journal-title":"Orphanet J Rare Dis"},{"key":"199_CR6","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1212\/01.wnl.0000194208.08904.0c","volume":"66","author":"MM McGovern","year":"2006","unstructured":"McGovern MM, Aron A, Brodie SE, Desnick RJ, Wasserstein MP (2006) Natural history of type A Niemann-Pick disease. Neurology 66:228\u2013232","journal-title":"Neurology"},{"key":"199_CR7","doi-asserted-by":"publisher","first-page":"e672","DOI":"10.1542\/peds.2004-0887","volume":"114","author":"MP Wasserstein","year":"2004","unstructured":"Wasserstein MP, Desnick RJ, Schuchman EH, Hossain S, Wallenstein S, Lamm C et al (2004) The natural history of type B Niemann-Pick disease: results from a 10-Year longitudinal study. Pediatrics 114:e672\u2013e677","journal-title":"Pediatrics"},{"key":"199_CR8","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1542\/peds.2007-3016","volume":"122","author":"MM McGovern","year":"2008","unstructured":"McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E et al (2008) A prospective, Cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 122:e341\u2013e349","journal-title":"Pediatrics"},{"key":"199_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10545-017-0123-6","volume":"41","author":"MP Wasserstein","year":"2018","unstructured":"Wasserstein MP, Diaz GA, Lachmann RH, Jouvin M, Nandy I, Ji AJ et al (2018) Olipudase Alfa for treatment of acid Sphingomyelinase deficiency (ASMD): safety and efficacy in adults treated for 30 months. J Inherit Metab Dis 41:829\u2013838","journal-title":"J Inherit Metab Dis"},{"key":"199_CR10","first-page":"46","volume":"56","author":"OCW Chen","year":"2020","unstructured":"Chen OCW, Colaco A, Davis LC, Kiskin FN, Farhat NY, Speak AO et al (2020) Defective platelet function in < Scp >Niemann-Pick disease type < Scp >C1. JIMD Rep 56:46\u201357","journal-title":"JIMD Rep"},{"key":"199_CR11","first-page":"1425","volume":"24","author":"M Wasserstein","year":"2022","unstructured":"Wasserstein M, Lachmann R, Hollak C, Arash-Kaps L, Barbato A, Gallagher RC et al (2022) A randomized, placebo-controlled clinical trial evaluating olipudase Alfa enzyme replacement therapy for chronic acid Sphingomyelinase deficiency (ASMD) in adults: One-year results. Genet Sci 24:1425\u20131436","journal-title":"Genet Sci"},{"key":"199_CR12","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s13023-022-02587-0","volume":"17","author":"GA Diaz","year":"2022","unstructured":"Diaz GA, Giugliani R, Guffon N, Jones SA, Mengel E, Scarpa M et al (2022) Long-term safety and clinical outcomes of olipudase Alfa enzyme replacement therapy in pediatric patients with acid Sphingomyelinase deficiency: two-year results. Orphanet J Rare Dis 17:437","journal-title":"Orphanet J Rare Dis"},{"key":"199_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/humu.22981","volume":"37","author":"JT den Dunnen","year":"2016","unstructured":"den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J et al (2016) HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 37:564\u2013569","journal-title":"Hum Mutat"},{"key":"199_CR14","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1148\/radiol.2381041696","volume":"238","author":"DS Mendelson","year":"2006","unstructured":"Mendelson DS, Wasserstein MP, Desnick RJ, Glass R, Simpson W, Skloot G et al (2006) Type B Niemann-Pick disease: findings at chest radiography, Thin-Section CT, and pulmonary function testing. Radiology 238:339\u2013345","journal-title":"Radiology"},{"key":"199_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jocd.2014.01.003","volume":"17","author":"NJ Crabtree","year":"2014","unstructured":"Crabtree NJ, Arabi A, Bachrach LK, Fewtrell M, El-Hajj Fuleihan G, Kecskemethy HH et al (2014) Dual-Energy X-Ray absorptiometry interpretation and reporting in children and adolescents: the revised 2013 ISCD pediatric official positions. J Clin Densitometry 17:225\u2013242","journal-title":"J Clin Densitometry"},{"key":"199_CR16","first-page":"1543","volume":"23","author":"GA Diaz","year":"2021","unstructured":"Diaz GA, Jones SA, Scarpa M, Mengel KE, Giugliani R, Guffon N et al (2021) One-year results of a clinical trial of olipudase Alfa enzyme replacement therapy in pediatric patients with acid Sphingomyelinase deficiency. Genet Sci 23:1543\u20131550","journal-title":"Genet Sci"},{"key":"199_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1210\/endrev\/bnab037","volume":"43","author":"AJ Berberich","year":"2022","unstructured":"Berberich AJ, Hegele RA (2022) A modern approach to dyslipidemia. Endocr Rev 43:611\u2013653","journal-title":"Endocr Rev"},{"key":"199_CR18","unstructured":"Clinical Trials Arena Xenpozyme (olipudase alfa) to Treat Acid Sphingomyelinase Deficiency (ASMD), Europe [Internet]. 2022 [cited 2025 Jun 25]. Available from: https:\/\/www.clinicaltrialsarena.com\/projects\/xenpozyme-olipudase-alfa-asmd\/?cf-view"},{"key":"199_CR19","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/humu.24192","volume":"42","author":"J Hu","year":"2021","unstructured":"Hu J, Maegawa GHB, Zhan X, Gao X, Wang Y, Xu F et al (2021) Clinical, biochemical, and genotype-phenotype correlations of 118 patients with Niemann\u2010Pick disease types A\/B. Hum Mutat 42:614\u2013625","journal-title":"Hum Mutat"},{"key":"199_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s41065-023-00272-1","volume":"160","author":"R Wang","year":"2023","unstructured":"Wang R, Qin Z, Huang L, Luo H, Peng H, Zhou X et al (2023) SMPD1 expression profile and mutation landscape help Decipher genotype-phenotype association and precision diagnosis for acid Sphingomyelinase deficiency. Hereditas 160:11","journal-title":"Hereditas"},{"key":"199_CR21","first-page":"100957","volume":"34","author":"Y-W Pan","year":"2023","unstructured":"Pan Y-W, Tsai M-C, Yang C-Y, Yu W-H, Wang B, Yang Y-J et al (2023) Enzyme replacement therapy for children with acid Sphingomyelinase deficiency in the real world: A single center experience in Taiwan. Mol Genet Metab Rep 34:100957","journal-title":"Mol Genet Metab Rep"},{"key":"199_CR22","first-page":"967","volume":"19","author":"MM McGovern","year":"2017","unstructured":"McGovern MM, Dionisi-Vici C, Giugliani R, Hwu P, Lidove O, Lukacs Z et al (2017) Consensus recommendation for a diagnostic guideline for acid Sphingomyelinase deficiency. Genet Sci 19:967\u2013974","journal-title":"Genet Sci"},{"key":"199_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40261-023-01270-x","volume":"43","author":"YY Syed","year":"2023","unstructured":"Syed YY (2023) Olipudase Alfa in Non-CNS manifestations of acid Sphingomyelinase deficiency: A profile of its use. Clin Drug Investig 43:369\u2013377","journal-title":"Clin Drug Investig"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-025-00199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-025-00199-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-025-00199-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:16:29Z","timestamp":1757456189000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-025-00199-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["199"],"URL":"https:\/\/doi.org\/10.1186\/s40348-025-00199-9","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the tenets of the Declaration of Helsinki 1964. The study was approved by Assiut University\u2019s Ethical Committee for Clinical Research. Signed statements of informed consent to participation and publication were obtained from the guardians of trial participants before the study. The consent requirement was waived for retrospective participants by the above-named ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"None of the authors has any potential conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of interest statement"}},{"value":"None of the authors has any potential conflict of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and declarations"}},{"value":"No financial support was received for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}],"article-number":"11"}}